ShanXi C&Y Pharmaceutical Group Co.,LTD. (SHE:300254)
China flag China · Delayed Price · Currency is CNY
7.42
-0.18 (-2.37%)
Nov 13, 2026, 3:04 PM CST

SHE:300254 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
794.95868.17842.33792.42824.84924.94
Other Revenue
2.622.624.286.894.155.43
797.57870.79846.61799.31829930.37
Revenue Growth
-6.09%2.86%5.92%-3.58%-10.90%9.71%
Cost of Revenue
279.53285.24283.21259.45251.21290.06
Gross Profit
518.04585.54563.39539.86577.79640.32
Selling, General & Admin
378.83416.12428.41453.44534.1603.92
Research & Development
49.3150.856.5349.9754.5257.12
Other Operating Expenses
5.014.49-0.374.8612.0912.77
Operating Expenses
435.59476.48490.35507.84601.43668.48
Operating Income
82.45109.0673.0432.02-23.64-28.16
Interest Expense
-22.43-21.63-16.98-33.16-46.06-49.17
Interest & Investment Income
7.364.225.8624.632.5515.74
Earnings From Equity Investments
-----3.43-
Currency Exchange Gain (Loss)
00-0.010.620
Other Non Operating Income (Expenses)
18.8416.1119.4918.51-2.08-0.2
EBT Excluding Unusual Items
86.23107.7681.4242-72.05-61.8
Impairment of Goodwill
---4.26-4.1-19.58-19.6
Gain (Loss) on Sale of Investments
-18.93-18.93----
Gain (Loss) on Sale of Assets
18.947.5118.80.69-0.37
Asset Writedown
-3.23-0.43-1.41-1.4-28.82-12.08
Other Unusual Items
-6.54-6.54-2.62-0.0229.7428.37
Pretax Income
58.5290.7980.6455.28-90.02-65.48
Income Tax Expense
21.5734.365.886.557.99.07
Earnings From Continuing Operations
36.9456.4474.7648.73-97.92-74.55
Minority Interest in Earnings
-14.61-31.59-32.57-23.53-20.6-16.89
Net Income
22.3324.8542.1925.2-118.52-91.44
Net Income to Common
22.3324.8542.1925.2-118.52-91.44
Net Income Growth
9.67%-41.10%67.45%---
Shares Outstanding (Basic)
245243242242237228
Shares Outstanding (Diluted)
247245242242237228
Shares Change
1.27%1.15%0.20%1.89%4.00%6.92%
EPS (Basic)
0.090.100.170.10-0.50-0.40
EPS (Diluted)
0.090.100.170.10-0.50-0.40
EPS Growth
8.29%-41.77%67.11%---

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
116.9262.4519.443.948.0959.99
Free Cash Flow Per Share
0.470.260.080.020.200.26
Gross Margin
64.95%67.24%66.55%67.54%69.70%68.82%
Operating Margin
10.34%12.52%8.63%4.00%-2.85%-3.03%
Profit Margin
2.80%2.85%4.98%3.15%-14.30%-9.83%
Free Cash Flow Margin
14.66%7.17%2.30%0.49%5.80%6.45%
EBITDA
133.08160.06124.5584.6134.6635.55
EBITDA Margin
16.68%18.38%14.71%10.59%4.18%3.82%
D&A For EBITDA
50.635151.5152.5958.363.71
EBIT
82.45109.0673.0432.02-23.64-28.16
EBIT Margin
10.34%12.52%8.63%4.00%-2.85%-3.03%
Effective Tax Rate
36.87%37.84%7.29%11.85%--
Revenue as Reported
797.57870.79846.61799.31829930.37
Advertising Expenses
-21.3812.745.674.888.44